Dr. Fred Silva joined Arkana Laboratories in 2011 following 12 years of service as the Executive Vice President and Secretary-Treasurer of the United States and Canadian Academy of Pathology. During that time, he also served as Adjunct Professor of Pathology at Emory University in Atlanta, as well as Visiting Clinical Professor at the Medical College of Georgia in Augusta. Dr. Silva received his BS and MD from the University of Oklahoma. He trained at Columbia University College of Physicians and Surgeons in New York City where he also served as Assistant Professor in Surgical and Renal Pathology. In 1980, he became Associate Professor and Director of Surgical Pathology at the University of Texas-Southwestern Medical Center in Dallas, a position he held for nine years. He then became the Lloyd Rader Professor and Chair of the Department of Pathology at the University of Oklahoma from 1989–1999.
At Arkana, Dr. Silva is heavily involved in fellow and visiting nephrologist/pathologist education as well as producing his Throwback Thursday podcast series. Dr. Silva has been instrumental in fellow research and study design during his tenure at Arkana as well. In our daily case conference, Dr. Silva is an unparalleled information repository with extensive knowledge of the nephrology and pathology literature and can often recite the progression of knowledge on varied disease states starting hundreds of years prior and move all the way to our current understanding, citing numerous important studies along the way. Outside of work, Dr. Silva is interested in cosmology and teaches several lectures involving the origin and development of the universe and our place in the ever-expanding cosmos and also enjoys spending time with his wife and family.
Dr. Silva was board certified by the American Board of Pathology in 1976. He has also published extensively in general surgical pathology and renal pathology and is Co-Editor/Author of four major textbooks/atlases in renal pathology.
Posted November 27th 2020
We are now offering IHC and ISH testing for evaluation of the presence of SARS-CoV-2 (aka COVID-19 and novel 2019 coronavirus).